Cardiovascular Research in Pigs

Cardiovascular research in pigs is essential due to their physiological similarities with humans, and the use of porcine models has directly advanced therapies for myocardial infarction (MI) and heart failure through cell-based interventions such as hiPSC-CM transplantation.

Cardiovascular diseases remain the leading cause of death globally, pushing scientists to explore innovative research models. Pigs have emerged as pivotal in this quest, thanks to their physiological similarities to humans. This connection has unlocked new pathways for understanding heart diseases and developing groundbreaking treatments.

The use of pigs in cardiovascular research is not just a scientific preference but a necessity. Their heart size, structure, and function closely mirror those of humans, making them ideal subjects for experimental studies and surgical simulations. This has propelled significant advancements in heart disease management, including the development of novel surgical techniques and medical devices.

As we investigate deeper into the area of cardiovascular research, the role of pigs is becoming increasingly indispensable. They bridge the gap between basic research and clinical applications, offering hope for millions affected by heart conditions. Their contribution is a testament to the power of cross-species research in solving complex health challenges.

Why are pigs ideal for cardiovascular research?

Pigs are highly valuable in cardiovascular studies owing to their heart anatomy, physiology, and genetic makeup, which closely mimic those of humans. Their heart-to-body weight ratio, right-dominant coronary circulation, and expression of β-myosin heavy chain (β-MHC) facilitate translational research for myocardial infarction and cardiac regeneration therapies. Additionally, genetically modified pig models have been successfully used for xenotransplantation trials and novel cardiac interventions.

Importance of Pigs in Cardiovascular Research

Biotech Farm LTD, a state-of-the-art large animal facility, has carved a niche in advancing drug and device R&D within the Israeli BioMed and Biotech Industry. With its inception rooted in the immense experience of its founders, Adir Koreh and Rinat Borenshtain-Koreh, the facility stands as a beacon for cardiovascular research in pigs. This specialized focus serves both large- and small-scale companies, propelling forward the health of mankind and animals alike.

The Significance of Pigs in Cardiovascular Investigations

At the core of Biotech Farm LTD’s services lies a profound understanding of the critical role that pigs play in cardiovascular research. Recognizing the physiological resemblances between human and pig hearts, the facility leverages these animals to bridge the gap between basic research and clinical applications. The aim is to not only enhance our understanding of heart diseases but also to develop innovative treatments that can eventually be translated into human care.

Tailored Services for Groundbreaking Research

Biotech Farm LTD offers a comprehensive suite of services tailored to support pre-regulatory large animal studies and GLP validation studies, crucial steps in the R&D process. Their well-equipped labs host an array of advanced technologies and devices essential for cardiovascular investigations. Also, the professional crew, with more than 30 years of experience, provides indispensable scientific support, ensuring that each study is conducted with meticulous attention to detail and adherence to the highest standards of research integrity.

• Pre-regulatory large animal studies: Pivotal for assessing the effectiveness and safety of new drugs and devices.
• GLP validation studies: Essential for ensuring that products meet the stringent guidelines required for regulatory approval.

Biotech Farm LTD’s commitment to advancing cardiovascular research in pigs reflects its broader dedication to the wellbeing of humans and animals. Through collaboration with both local and international partners, they aim to spearhead innovations that could lead to breakthroughs in the management and treatment of heart diseases. With each study, Biotech Farm LTD reinforces its role as a crucial link between innovative ideas and tangible healthcare solutions.

Physiological Similarities to Humans

Biotech Farm LTD stands at the forefront of Cardiovascular Research in Pigs, leveraging the species’ remarkable physiological similarities to humans. These similarities are fundamental in translating preclinical findings into potential clinical breakthroughs, especially in the area of heart disease.

Pigs and humans share a close genetic makeup that influences cardiovascular systems significantly. This genetic resemblance ensures that the cardiovascular anatomy and function in pigs closely mirror human systems. For example, the size, heart rate, and the blood pressure of pigs are comparable to those of humans, making them invaluable models for cardiovascular studies.

Also, the pathological progression of cardiovascular diseases in pigs aligns with that in humans. Diseases such as atherosclerosis and myocardial infarction develop in pigs under similar conditions to humans, providing a realistic model for studying disease mechanisms and therapeutics. This similarity accelerates the development of drugs and devices designed to combat heart diseases, facilitating faster transitions from laboratory research to clinical trials.

Biotech Farm LTD offers a comprehensive suite of services that cater to the specific needs of Cardiovascular Research in Pigs. These include:

• Pre-regulatory large animal studies
• GLP validation studies
• Advanced technological support for cardiovascular investigations

Equipped with state-of-the-art facilities and a professional crew dedicated to advancing R&D, Biotech Farm LTD ensures the reliability and relevance of cardiovascular findings in pigs. Their collaborations with both large and small-scale companies domestically and internationally underscore their commitment to the betterment of human and animal health.

The profound physiological similarities between pigs and humans underscore the critical role of pigs in bridging basic research with clinical applications. Through the specialized services and collaborative efforts provided by Biotech Farm LTD, researchers are well-equipped to pioneer the next wave of innovations in heart disease management.

Advancements in Heart Disease Management

Biotech Farm LTD, a leader in large animal facility management, is at the forefront of cardiovascular research in pigs. Established by Adir Koreh and Rinat Borenshtain-Koreh, the facility boasts over 30 years of experience in research leadership and management. Biotech Farm LTD provides comprehensive services to support drugs and devices R&D, specializing in pre-regulatory large animal studies and GLP validation studies. They cater to both large and small-scale companies in Israel and abroad, aiming to enhance healthcare for humans and animals alike.

Tailored Solutions for Cardiovascular Research

The state-of-the-art facility of Biotech Farm LTD is specifically designed to accommodate cardiovascular research in pigs. Pigs are increasingly recognized for their similarities to humans in terms of genetic makeup, heart disease progression, and the overall anatomical structure of the heart. These similarities make pigs excellent models for studying cardiovascular diseases, testing new treatments, and developing medical devices.

Biotech Farm LTD offers:

• Specialized Services: Tailored for cardiovascular research, these include pre-regulatory studies that are crucial for advancing to clinical trials.
• Advanced Technological Support: The facility is equipped with cutting-edge technology and tools necessary for comprehensive cardiovascular research, including imaging and diagnostics equipment.
• Professional Crew: A dedicated team of scientists and technicians supports researchers in every step of the development process. Their expertise ensures that all studies meet the highest scientific and ethical standards.

The collaborative approach adopted by Biotech Farm LTD aims to accelerate the translation of research findings into real-world applications. By focusing on cardiovascular research in pigs, Biotech Farm LTD is actively contributing to the advancement of heart disease management, potentially saving millions of lives.

What are the advantages and limitations of porcine models?

The advantages of porcine models include:

• High anatomical fidelity to human heart structure (supported by successful xenotransplantation trials).
• Clinically relevant physiology and genetics (β-MHC expression, similar contractile properties).
• Established protocols for cardiac imaging and monitoring in research (e.g., echocardiography).

Limitations include:

• Susceptibility to ventricular fibrillation, affecting mortality rates.
• High maintenance and growth rates for some breeds (farm pigs can reach >100 kg within months).
• Costs and husbandry requirements, particularly for immunocompromised models.

Pigs as Indispensable Research Models

In the area of cardiovascular research, pigs have emerged as pivotal models due to their remarkable anatomical and physiological resemblance to humans. This similarity extends to their cardiovascular system, making pigs indispensable in advancing understanding and treatment of heart disease. Biotech Farm LTD, a state-of-the-art facility, stands at the forefront of utilizing pigs for such critical research endeavors.

Biotech Farm LTD provides a comprehensive environment for cardiovascular research in pigs. The facility is well-equipped with the latest technology and managed by a professional crew dedicated to supporting the R&D of drugs and devices. This specialized focus on pre-regulatory large animal studies and GLP validation studies ensures that the research not only adheres to the highest scientific standards but also paves the way for groundbreaking advancements in cardiovascular health.

The founders of Biotech Farm LTD, Adir Koreh and Rinat Borenshtain-Koreh, bring over 30 years of experience in managing and leading research projects. Their expertise is instrumental in guiding the facility’s emphasis on cardiovascular research in pigs. By working closely with both large- and small-scale companies in Israel and abroad, Biotech Farm LTD contributes significantly to the development of treatments that can benefit mankind and animals alike.

Cardiovascular research in pigs at Biotech Farm LTD involves a series of methodical processes, from the initial stages of drug and device development to the critical phases of pre-regulatory and GLP validation studies. This meticulous approach ensures that every aspect of the research is conducted with precision, fostering innovations that could potentially revolutionize the management of heart disease.

Through their dedication to high-quality research and scientific support, Biotech Farm LTD has become an essential partner for companies engaging in cardiovascular research. Their use of pigs as research models not only reflects a commitment to advancing healthcare but also highlights the importance of cross-species insights into heart disease management.

Future of Cardiovascular Research with Pigs

At Biotech Farm LTD, the future of cardiovascular research shines brightly, powered by the innovative use of pigs as core models for understanding heart disease. This serves as a cornerstone for the facility’s relentless pursuit to revolutionize cardiovascular health. Cardiovascular research in pigs not only bridges the gap between theoretical studies and practical solutions but also accelerates the development of life-saving treatments.

Biotech Farm LTD, under the visionary leadership of Adir Koreh and Rinat Borenshtain-Koreh, has established itself as a beacon of hope in the area of cardiovascular research. With over three decades of experience in research management and collaboration, they have carved a niche in

 and GLP validation studies. The facility is exceptionally equipped to handle the intricacies of cardiovascular research in pigs, making it a revered partner for both local and international biomed and biotech industries.

• State-of-the-Art Facilities: Biotech Farm LTD boasts well-equipped laboratories and research spaces designed to help comprehensive cardiovascular studies.
• Expertise and Experience: The professional crew at Biotech Farm LTD is unmatched in their dedication to advancing cardiovascular health, offering a wealth of knowledge and expertise.
• Global Collaboration: Working with a range of companies, from startups to established enterprises, Biotech Farm LTD plays a pivotal role in the global effort to combat heart disease.

Through their commitment to providing scientifically supportive services, Biotech Farm LTD ensures that each study not only adheres to the highest standards of quality but also contributes significantly to the collective understanding of cardiovascular diseases. By focusing on pigs as a model for research, the facility leverages anatomical and physiological similarities with humans to explore innovative treatment methods and devices.

Cardiovascular research in pigs at Biotech Farm LTD encapsulates a future where heart disease can be managed more effectively, potentially saving millions of lives each year. Through meticulous research processes, cutting-edge technology, and global collaboration, Biotech Farm LTD continues to pave the way for groundbreaking advancements in cardiovascular health.

Which pig breeds are most commonly used?

Common breeds are:

• Farm breeds: Yorkshire, Landrace — suitable for short-term engraftment and early survival studies.
• Miniature pigs: Göttingen, Sinclair — used for long-term cardiac functional assessment (8–12 weeks), enabling extended follow-up for cell-based regenerative therapies.

Breed	Growth Rate	Study Duration	Use Case
Yorkshire	1–2 kg → >100 kg/4 mo	1–4 weeks	Early engraftment, safety
Minipigs	0.5–1 kg → 7–20 kg/4mo	8–12 weeks	Long-term cardiac function analysis

How are MI models induced and assessed in pigs?

Procedures to induce MI in pigs include:

• Open-chest surgical ligation of coronary arteries or cryoinjury.
• Catheter-guided coronary occlusion for less invasive, clinically relevant ischemia.

Outcomes are monitored through advanced imaging modalities, such as cardiac MRI and echocardiography, which yield data analogous to clinical human studies. Parameters tracked include ventricular volumes, ejection fraction, wall thickness, and Doppler blood flow, ensuring robust translational outcomes.

What are recent findings in cardiac regeneration using porcine models?

Studies using hiPSC-CM transplantation have shown:

• Improved left ventricular function, reduced scar size, and increased angiogenesis in both farm pig and minipig models after MI.
• Engraftment is often better in genetically modified pigs with tailored immunosuppressive regimens.
• Multi-cellular cardiac patches and cell sheets combining hiPSC-derived cardiomyocytes, endothelial cells, and smooth muscle cells can offer major improvements without inducing arrhythmias.

What are the critical considerations for translational research?

• Immunosuppression: Both drug-based regimens and transgenic immunocompromised pigs are used, with variable success in cell survival.
• Method of cell delivery: Patch-based epicardial, intramyocardial, and hydrogel-supported techniques each influence engraftment and cardiac function improvement.
• Timing: Delivery post-MI between 1–4 weeks is most clinically relevant for regeneration studies.

The use of porcine models for cardiovascular research at Biotech Farm Ltd. is a state-of-the-art, ethical, and scientifically robust approach that continues to advance both basic science and clinical applications in cardiac medicine.

How Is Biotech Farm Redefining the Future of Cardiovascular Research?